首页> 外文期刊>Viral Immunology >Virus-Like Particle Vaccine Comprised of the HA, NA, and M1 Proteins of an Avian Isolated H5N1 Influenza Virus Induces Protective Immunity Against Homologous and Heterologous Strains in Mice
【24h】

Virus-Like Particle Vaccine Comprised of the HA, NA, and M1 Proteins of an Avian Isolated H5N1 Influenza Virus Induces Protective Immunity Against Homologous and Heterologous Strains in Mice

机译:禽流感分离的H5N1流感病毒的HA,NA和M1蛋白组成的类似病毒的颗粒疫苗可诱导小鼠抗同种和异种菌株的保护性免疫

获取原文
获取原文并翻译 | 示例
           

摘要

Highly pathogenic avian influenza H5N1 virus represents a growing threat for an influenza pandemic. Development of effective vaccines for H5N1 is a priority for pandemic preparedness. Focusing on influenza virus-like particles (VLPs) has been suggested as a promising vaccine approach. Recent VLP vaccination efforts have been concentrated on the H5N1 strains isolated from humans. Because all confirmed cases of human H5N1 infection were directly transmitted from infected poultry, it is of interest to develop VLP vaccines comprised of antigenic proteins of avian H5N1 strains in order to compare their efficacy in fighting diverse H5N1 strains with vaccines developed using human isolates. In this study, we generated a VLP vaccine composed of the HA, NA, and M1 proteins of the avian H5N1 influenza virus isolate A/chicken/Hubei/489/2004, which seems to occupy a unique phylogenetic position; it belongs to neither clade 1 nor clade 2. Upon infection of Sf9 insect cells using recombinant baculoviruses, the co-expressed HA, NA, and M1 proteins self-assembled and released into the culture medium as VLPs. In a mouse model, purified VLPs elicited an effective antibody response and conferred complete protection against heterologous human H5N1 influenza virus, as well as a homologous avian H5N1 influenza virus isolate. Our work provides further evidence that vaccination with influenza VLPs may be a productive approach to achieve protection against diverse H5N1 strains.
机译:高致病性禽流感H5N1病毒对流感大流行构成越来越大的威胁。为H5N1疫苗开发有效疫苗是大流行防范的重点。有人建议将重点放在流感病毒样颗粒(VLP)上作为一种有前途的疫苗方法。最近的VLP疫苗接种工作集中在从人类分离的H5N1菌株上。由于所有确诊的人类H5N1感染病例都是直接从受感染的禽类传播的,因此有兴趣开发由禽H5N1株抗原蛋白组成的VLP疫苗,以便比较它们与使用人类分离株开发的疫苗对抗多种H5N1株的功效。在这项研究中,我们产生了一种由禽H5N1流感病毒分离株A / chicken / Hubei / 489/2004的HA,NA和M1蛋白组成的VLP疫苗,它似乎占据了独特的系统发生地位。它既不属于进化枝1,也不属于进化枝2。在用重组杆状病毒感染Sf9昆虫细胞后,共表达的HA,NA和M1蛋白自组装并以VLP形式释放到培养基中。在小鼠模型中,纯化的VLP引发有效的抗体反应,并针对异源人类H5N1流感病毒以及同源禽类H5N1流感病毒分离株提供了全面保护。我们的工作提供了进一步的证据,表明接种流感VLP疫苗可能是针对多种H5N1毒株提供保护的有效方法。

著录项

  • 来源
    《Viral Immunology》 |2009年第4期|273-281|共9页
  • 作者单位

    These authors contributed equally to this work.;

    These authors contributed equally to this work.;

    State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Luojia Hill, Wuchang District, Wuhan City, HuBei, China.;

    State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Luojia Hill, Wuchang District, Wuhan City, HuBei, China.;

    State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Luojia Hill, Wuchang District, Wuhan City, HuBei, China.;

    State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Luojia Hill, Wuchang District, Wuhan City, HuBei, China.;

    State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Luojia Hill, Wuchang District, Wuhan City, HuBei, China.;

    State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Luojia Hill, Wuchang District, Wuhan City, HuBei, China.;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号